Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 2, 2013, Pages 251-259

  Hatoum, Hind T ^a   Crawford, E David ^b   Nielsen, Sandy Kildegaard ^c   Lin, Swu Jane ^d   Marshall, Dennis C ^e  

^a Hind T Hatoum and Company   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c European Market Access Ferring International Center SA   (Switzerland)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Ferring Pharmaceuticals Inc USA   (United States)

Author keywords

androgen deprivation therapy; cost effectiveness; degarelix; Markov simulation models; prostate cancer; quality adjusted life years

Indexed keywords

BICALUTAMIDE; BUSERELIN; DEGARELIX; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DISTANT METASTASIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; GYNECOMASTIA; HUMAN; ORCHIECTOMY; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ANDROGEN ANTAGONISTS; COST-BENEFIT ANALYSIS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; TESTOSTERONE;

EID: 84876147465     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.13.12     Document Type: Review

References (39)

1. Yan B, Noone AM, Yee C, Banerjee M, Schwartz K, Simon MS. Racial differences in colorectal cancer survival in the Detroit metropolitan area. Cancer 115(16), 3791-3800 (2009
2. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9(Suppl. 1), S3-S8 (2007
3. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J. Natl Compr. Canc. Netw. 8(2), 211-223 (2010
4. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 75(3), 642-647 (2010
5. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59(4), 572-583 (2011
6. Pommerville PJ, de Boer JG. GnRH antagonists in the treatment of advanced prostate cancer. Can. J. Urol. 17(2), 5063-5070 (2010
7. Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57(5), 836-842 (2010
8. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 108(6), 806-813 (2011
9. Konski A. Cost-effectiveness of intensitymodulated radiation therapy. Expert Rev. Pharmacoecon. Outcomes Res. 5(2), 137-140 (2005
10. Purmonen TT. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 383-393 (2011
11. Iskedjian M, Hemels M, Iscoe N, Fleshner N, Einarson T. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer. Value Health 5(3), 197 (2002
12. Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson T. Cost-utility analysis of LHRH agonists in the treatment of metastatic prostate cancer. Value Health 5(3), 129 (2002
13. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl Cancer Inst. 92(21), 1731-1739 (2000
14. Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 45(4), 633-640 (1995
15. Konski A, Sherman E, Krahn M et al. Economic analysis of a Phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int. J. Radiat. Oncol. Biol. Phys. 63(3), 788-794 (2005
16. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J. Urol. 174(2), 547-552; discussion 552 (2005
17. Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 106(1), 51-57 (2006
18. Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 66(4), 835-839 (2005
19. Iannazzo S, Pradelli L, Carsi M, Perachino M. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value Health 14(1), 80-89 (2011
20. Lu L, Peters J, Roome C, Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 109(8), 1183-1192 (2012
21. Fisher D, Brereton NJ, Nielsen SK, Tate E. A cost utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in Scotland. Presented at: ISPOR 14th Annual European Congress. Madrid, Spain, 5-8 November 2011
22. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M. Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 11(3), 233-248 (2002
23. Samant RS, Dunscombe PB, Roberts GH. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol. Oncol. 21(3), 171-177 (2003
24. Grosse SD. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8(2), 165-178 (2008
25. Weinstein MC, O'Brien B, Hornberger J et al.; ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6(1), 9-17 (2003
26. Patrick DL, Burke LB, Powers JH et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl. 2), S125-S137 (2007
27. Watkins JB. Creating models that meet decision makers' needs: A US payer perspective. Value Health 15(6), 792-793 (2012
28. Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health 13(5), 613-623 (2010
29. Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994-2004. Med. Decis. Making 28(5), 713-722 (2008
30. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. JAMA 302(13), 1437-1443 (2009
31. Williams I, Bryan S, McIver S. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J. Health Serv. Res. Policy 12(2), 73-79 (2007
32. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J. Clin. Oncol. 25(2), 191-195 (2007
33. Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J. Clin. Oncol. 28(20), 3234-3238 (2010
34. Drummond M, Weatherly H. Implementing the findings of health technology assessments. If the CAT got out of the bag, can the TAIL wag the dog? Int. J. Technol. Assess. Health Care 16(1), 1-12 (2000
35. Grol R, Grimshaw J. From best evidence to best practice: Effective implementation of change in patients' care. Lancet 362(9391), 1225-1230 (2003
36. Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. Int. J. Technol. Assess. Health Care 17(1), 38-55 (2001
37. Claxton K, Sculpher M, Culyer A et al. Discounting and cost-effectiveness in NICE- stepping back to sort out a confusion. Health Econ. 15(1), 1-4 (2006
38. Hoomans T, Ament AJHA, Evers SMAA, Severens JL. Worthwhile implementation of evidence-based guidelines into clinical practice: How to determine the investment potential for guideline implementation and value for money of implementation strategies? Presented at: The International Health Economics Association 6th World Congress. Copenhagen, Denmark, 8-11 July 2007
39. Hoomans T, Fenwick EA, Palmer S, Claxton K. Value of information and value of implementation: Application of an analytic framework to inform resource allocation decisions in metastatic hormonerefractory prostate cancer. Value Health 12(2), 315-324 (2009